International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial
This study evaluated the toxicity and quality of life (QOL) with CyberKnife-based SBRT and simultaneous integrated boost in localised prostate cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 15, 2024 Category: Radiology Authors: Binnaz Yasar, Yae-Eun Suh, Ewan Chapman, Luke Nicholls, Daniel Henderson, Caroline Jones, Kirsty Morrison, Emma Wells, Julia Henderson, Carole Meehan, Aslam Sohaib, Helen Taylor, Alison Tree, Nicholas Van As Tags: Clinical Investigation Source Type: research

A Randomized Trial Comparing Quality of Life After LDR or HDR Prostate Brachytherapy Boost with Pelvic External Beam Radiation Therapy
To compare health-related Quality of Life (QoL) in urinary, bowel and sexual domains after combined external beam radiotherapy (EBRT) and either low dose rate (LDR) or high dose rate (HDR) prostate brachytherapy (BT). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 15, 2024 Category: Radiology Authors: Juanita Crook, Nikitha Moideen, Greg Arbour, Felipe Castro C ánovas, Cynthia Araujo, Deidre Batchelar, Ross Halperin, Michelle Hilts, David Kim, David Petrik, Jim Rose, JC Cheng, Francois Bachand Tags: Clinical Investigation Source Type: research

Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Most patients with diffuse large B-cell lymphoma (DLBCL) experience excellent outcomes with first-line immunochemotherapy-based regimens that usually include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and frequently consolidation radiation therapy (RT) to sites at higher risk of local relapse.1-7 Despite these optimal efforts, however, approximately 30% to 40% of patients may experience relapse or primary refractory disease.8 For fit patients, the standard treatment approach in this scenario is usually high-dose chemotherapy and autologous stem cell rescue/transplantation. (Source: Inter...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Rahul R. Parikh, Sarah A. Milgrom, Belinda A. Campbell Tags: Oncology Scan Source Type: research

What You See Ain't Necessarily What You Got
This issue of the Red Journal presents novel combinatorial approaches (eg, advanced imaging with sophisticated planning and delivery tools). We herein take this opportunity to again highlight (1) our tendency toward an overreliance on imaging and (2) the utility of continuing to extend beyond imaging to incorporate anatomic and physiological concepts into the treatment planning process.1,2 (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Lawrence B. Marks, Shiva K. Das, Joel E. Tepper Tags: Editorial Source Type: research

By Your Powers Combined: Treating Pelvic Osteosarcoma With Combination Radiation and Thermoablation
A 77-year-old man with a history of diabetes, atrial fibrillation, heart failure with preserved ejection fraction, and class III obesity presented with 6 months of right groin pain. MRI showed a 10.5  × 6.9 × 12.1-cm tumor of the right pubis and ischium with soft-tissue extension involving the femoral acetabular joint, pelvic sidewall, obturator internus, adductor muscles, and abutting the prostate gland (Fig. 1). Core-needle biopsy confirmed a high-grade osteosarcoma. A positron emiss ion tomography/computed tomography scan demonstrated a fluorodeoxyglucose-avid lesion without distant metastases (stage III, T3bN...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Elaine J. Chiao, Jeremy Harris Tags: Gray Zone Source Type: research

Letting Radiation Therapy “Make Its Bones”
For nonmetastatic unresectable pelvic osteosarcoma, we approach local therapy with curative intent to prevent the devastating consequences of local tumor progression, accepting that less than 20% of patients with unresectable disease are long-term survivors.1 Reports of success with definitive radiation therapy (RT) vary widely, but modern series have achieved 5-year local control exceeding 60% to 70% with definitive doses of proton RT (>65-70 Gy).2,3 Indeed, RT is the only local control modality mentioned by the National Comprehensive Cancer Network guidelines for unresectable osteosarcoma. (Source: International Journal ...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Pranathi Rao, Anusha Kalbasi Tags: Gray Zone Source Type: research

Combined Complementary Local Therapies for Pain Palliation and Local Control of a Pelvic Osteosarcoma
Radiation therapy (RT) has been the gold standard for the nonsurgical treatment and palliation of metastatic bone lesions.1 In the past decade, minimally invasive, percutaneous image guided ablation (eg, radiofrequency, microwave, and cryoablation) has also become part of the multidisciplinary treatment algorithm and is included in many of the histology treatment recommendations in the National Comprehensive Cancer Network guidelines. As used in this case, cryoablation would be the choice of thermal ablation because it allows visualization of the ablation zone on computed tomography and the ability to sculpt and create lar...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Jack W. Jennings Tags: Gray Zone Source Type: research

Improving the Treatment of Brain Metastases in HER2-Positive Breast Cancers: Eternal Dream or Reality? Results of the NRG Oncology –KROG/RTOG 1119 Phase 2 Randomized Trial and Future Directions
The results of the NRG Oncology –KROG/RTOG 1119 phase 2 randomized trial are of great interest and are opening the door of the eternal question of whether we can improve the response of radiation therapy using its association with adapted targeted treatments in the treatment of brain metastases (BM) of breast cancer.1 (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Youlia M. Kirova, Pierre Loap Tags: Editorial Source Type: research

Undoing the Layers: Magnetic Resonance Imaging/Advanced Image Guidance and Adaptive Radiation Therapy
As novel technologies and next-generation magnetic resonance imaging (MRI) and computed tomography (CT) guidance have evolved in the past 10 years, these technologies open the door to pivotal questions: What are the benefits of advanced CT- or MRI-guided radiation therapy? How can we apply adaptive radiation therapy to have the highest relative clinical impact? (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Lauren E. Henke Tags: Editorial Source Type: research

When Your Powers Are Limited, Gather All You Have in Hand
In this case report, the authors describe a challenging scenario in which a 77-year-old patient with multiple medical comorbidities presented with pelvic osteosarcoma, a rare radioresistant bone tumor, and the known-effective therapies including multiagent chemotherapy and definitive surgical resection could not be done because of the patient's age and medical conditions.1 This tumor was large, and the location and extent of the tumor dictated that for complete resection, this would have been a high-morbidity, high-risk surgery, an internal hemipelvectomy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Meng Xu-Welliver Tags: Letter to the Editor Source Type: research

“Bone Voyage:” Perfecting the Solo Act of Radiation Therapy for Older Patients With Unresectable Osteosarcoma
Although this patient has a high risk of distant metastasis given the lack of systemic therapy, local progression will be associated with significant morbidity, so an attempt at local control should be maximized.1 For this patient, I would have recommended upfront radiation therapy, with reservation of interventional procedures for local recurrence, should it occur. An interventional procedure could be considered combined with radiation therapy upfront if it effectively ablates a region that is dose limited, such as the near bowel; however, regions challenging for radiation therapy are also often difficult to adequately ab...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Shauna R. Campbell Tags: Letters to the Editor Source Type: research

Head and Neck abstracts Title Page
(Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Source Type: research

Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
The PD-1 inhibitor pembrolizumab (pembro) is approved as first-line monotherapy for patients (pts) with PD-L1-expressing R/M HNSCC (PD-L1 combined positivity score [CPS] ≥1). A phase 1b/2 study of pembro plus the multikinase inhibitor lenvatinib (len) showed promising antitumor activity and manageable toxicity in pts with HNSCC. In LEAP-010, a phase 3, randomized, placebo-controlled, double-blind study, we hypothesized that first-line len + pembro would improv e efficacy compared with placebo + pembro, and have a manageable safety profile, in pts with PD-L1 CPS ≥1 R/M HNSCC (NCT04199104). (Source: International...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L. Licitra, M. Tahara, K. Harrington, M. Olivera Hurtado de Mendoza, Y. Guo, S. Aksoy, M. Fang, B. Żurawski, T. Csőszi, M. Klochikhin, T.B. de Oliveira, S. Takahashi, M.H. Yang, P.L. Swiecicki, K. O'Hara, J. Shen, A. Wang, B. Gumuscu, K. Benjamin, R.I. Tags: 1 Source Type: research

Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis
Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial growth factor receptor tyrosine kinase inhibitors have immunomodulatory properties and may improve clinical outcomes in combination with anti-PD-1 therapy. Pembrolizumab and cabozantinib were well tolerated and showed promising clinical activity in patients with RMHNSCC in our reported phase 2 trial. Baseline CD8+ T cell infiltration correlated with overall response rate (ORR) (p=0.0512). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.F. Saba, A. Ekpenyong, A. McCook, N.C. Schmitt, J.H. Gross, S.F. Rudra, W.A. Stokes, K. Kirtane, R. Chaudhary, M. Biernacki, R. Slebos, X. Song, C. Steuer, D.M. Shin, Y.F. Teng, Y. Liu, C.H. Chung Tags: 2 Source Type: research

Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembro)  + Carboplatin (carbo) + Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
The standard-of-care (SOC) first-line treatment (1L) for R/M HNSCC consists of pembrolizumab (pembro)  + platinum + fluorouracil (5-fluorouracil). However, 5-fluorouracil is associated with potential administration complications and related toxicity, creating the need for alternative chemotherapy combinations. The global, prospective phase 4 KEYNOTE-B10 study (NCT04489888) evaluated pembro  + carboplatin (carbo) + paclitaxel (pacli) as 1L therapy for R/M HNSCC. Interim results of KEYNOTE-B10 showed promising antitumor activity for the initial 82 patients and manageable safety after a median follow-up of 8 m...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Dzienis, J. Cundom, C.S. Fuentes, A. Spreafico, M.J. Nordlinger, A.V. Pastor, E. Alesi, A. Neki, A.S. Fung, I.P. Figueiredo Lima, P. Oppelt, G.F. da Cunha Junior, F.A. Franke, J. Tseng, A.J. Joshi, J. McCarthy, Y. Sidi, B. Gumuscu, N. Naicker, G. de Ca Tags: 3 Source Type: research